A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
A Phase 3, Randomized, Open Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) Followed by Nivolumab Plus Ipilimumab or Nivolumab Plus CCRT Followed by Nivolumab vs CCRT Followed by Durvalumab in Previously Untreated, Locally Advanced Non-small Cell Lung Cancer (LA NSCLC)
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
CABA, Buenos Aires C1426ANZ, Argentina
Caba, Distrito Federal 1430, Argentina
N.Kifissia, 14564, Greece
Kurume-shi, Fukuoka 8300011, Japan
Hidaka-shi, Saitama 3501298, Japan
Kitaadachi-gun, Saitama 3620806, Japan
Bunkyo-ku, Tokyo 113-8603, Japan
Chuo-ku, Tokyo 1040045, Japan
Df, Mexico City 06720, Mexico
Maastrict, 6229 HX, Netherlands
Hato Rey, 00917, Puerto Rico
Floresti/ Cluj, 407280, Romania
KaohsiungCity, 83301, Taiwan